Valuation: Damora Therapeutics, Inc.

Market Cap 1.36B 1.22B 1.12B 1.02B 1.9B 129B 1.93B 13.45B 5.36B 67.57B 5.09B 4.98B 214B P/E 2026 *
-11x
P/E 2027 * -10.6x
Enterprise Value 894M 802M 742M 672M 1.25B 85.16B 1.27B 8.87B 3.53B 44.56B 3.36B 3.28B 141B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
91.57%
Yield 2026 *
-
Yield 2027 * -
1 day-1.59%
1 week+0.37%
Current month+1.55%
1 month+4.14%
3 months-26.55%
6 months-10.81%
Current year-6.08%
1 week 20.23
Extreme 20.2301
22.51
1 month 17.49
Extreme 17.49
22.68
Current year 16.5
Extreme 16.5001
34.89
1 year 4.95
Extreme 4.95
38.33
3 years 2.01
Extreme 2.01
38.33
5 years 2.01
Extreme 2.01
92.5
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 2026-03-29
Director of Finance/CFO - 2026-04-30
Chief Tech/Sci/R&D Officer 60 2026-01-04
Director TitleAgeSince
Chairman 40 2026-03-22
Director/Board Member 42 2025-11-09
Director/Board Member 41 2025-11-09
Date Insider Type Main position Quantity % Market Cap. Importance
9/25/26 Buy

Chief Executive Officer

12,500 0.0202%
8/12/26 Free

Director

30,350 0.0493%
7/6/26 Sell

General Counsel

-245 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-1.59%+0.37%+201.82%+61.30% 1.36B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+0.87%+27.92%+57.51% 44.75B
+2.00%-3.39%+17.83%+100.08% 41.62B
+1.34%-2.86%+224.43%+928.45% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +3.92%+0.25%+66.93%+152.45% 38.18B
Weighted average by Cap. +3.20%-0.27%+47.89%+160.83%

Financials

2026 *2027 *
Net sales - -
Net income -126M -113M -104M -94.32M -176M -11.96B -178M -1.25B -496M -6.26B -471M -461M -19.86B -151M -136M -125M -114M -212M -14.41B -215M -1.5B -598M -7.54B -568M -556M -23.94B
Net Debt -462M -414M -383M -347M -648M -43.96B -656M -4.58B -1.82B -23B -1.73B -1.7B -73.03B -352M -316M -292M -264M -494M -33.5B -500M -3.49B -1.39B -17.53B -1.32B -1.29B -55.66B
Projected Income Statement - Annual - Damora Therapeutics, Inc.
Logo Damora Therapeutics, Inc.
Damora Therapeutics, Inc. is a biotechnology company that focuses on hematologic disorders. It is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Its lead asset, DMR-001, is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR). It is developing candidates for treatment of essential thrombocythemia (ET), an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. DMR-002, an afucosylated antibody designed to enhance antibody-dependent cellular cytotoxicity and amplify natural immune killing of malignant cells. DMR-003, a bi-specific T-cell engager antibody designed to recruit and direct T-cell-mediated killing of malignant cells.
Employees
7
Date Price Change Volume
26-10-28 US$21.61 -1.59% 341,763
26-10-27 US$21.96 +3.29% 286,093
26-10-26 US$21.26 +0.81% 641,720
26-10-23 US$21.09 -2.86% 359,785
26-10-22 US$21.71 +0.84% 420,641
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Damora Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.96USD
Average target price
46.89USD
Spread / Average Target
+113.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Damora Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. DMRA Stock